Saverna Therapeutics

Saverna Therapeutics is an active Swiss biotech company (founded 2017) specializing in AI- and NMR-driven discovery of small molecules that target non-coding RNA, with a principal focus on miR-155 for systemic lupus erythematosus. Their main asset, the BUTTERFLY project, is currently at pre-clinical stage and aims to deliver the first-in-class small molecule inhibitor of a microRNA. Their technology platform combines machine learning, fragment-based screening, and nuclear magnetic resonance to enable rapid discovery of RNA-binding drugs. Notable partners include SpiroChem and Redoxis, with institutional support from Eurostars and Viva BioInnovator. No clinical or commercialized products yet; the company is pre-revenue, and employee numbers and other financial metrics are not disclosed in public sources.